Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment.


Journal

Experimental hematology
ISSN: 1873-2399
Titre abrégé: Exp Hematol
Pays: Netherlands
ID NLM: 0402313

Informations de publication

Date de publication:
03 2022
Historique:
received: 06 07 2021
revised: 17 12 2021
accepted: 18 12 2021
pubmed: 25 12 2021
medline: 11 3 2022
entrez: 24 12 2021
Statut: ppublish

Résumé

The Covid-19 pandemic has caused millions of deaths worldwide. Although vaccines have been developed, patients on immunosuppressive therapy are less likely to respond. This study was aimed at investigating the efficacy of a Covid-19 vaccine (Pfizer-BioNTech) in patients with non-Hodgkin lymphoma treated with anti-CD20 monoclonal antibodies. Only 1 of 28 lymphoma patients (3.6%) developed a seropositive response, compared with 100% (28/28) of the healthy volunteers. The low levels of CD19

Identifiants

pubmed: 34952139
pii: S0301-472X(21)00855-9
doi: 10.1016/j.exphem.2021.12.396
pmc: PMC8691955
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
COVID-19 Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

20-23

Informations de copyright

Copyright © 2021 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest disclosure The authors declare no competing financial interests.

Références

J Clin Exp Hematop. 2009 May;49(1):9-13
pubmed: 19474512
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Br J Haematol. 2005 Jul;130(1):96-8
pubmed: 15982350
Am J Hematol. 2021 Oct 1;96(10):1195-1203
pubmed: 34185336
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
J Clin Immunol. 2007 May;27(3):339-46
pubmed: 17345151
Blood. 2012 Aug 30;120(9):1954-7
pubmed: 22936740
Ann Rheum Dis. 2021 Oct;80(10):1355-1356
pubmed: 33958323
Blood Adv. 2021 Jun 21;5(12):2624-2643
pubmed: 34152403
Blood. 2011 Dec 22;118(26):6769-71
pubmed: 22058114

Auteurs

Ariella Tvito (A)

Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel. Electronic address: ariellat@szmc.org.il.

Aaron Ronson (A)

Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.

Renan Ghosheh (R)

Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.

Mira Kharit (M)

Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.

Jakob Ashkenazi (J)

Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.

Sophie Magen (S)

Immunology Laboratories, Shaare Zedek Medical Center, Jerusalem, Israel.

Ellen Broide (E)

Immunology Laboratories, Shaare Zedek Medical Center, Jerusalem, Israel.

Emmanuel Benayoun (E)

Immunology Laboratories, Shaare Zedek Medical Center, Jerusalem, Israel.

Jacob M Rowe (JM)

Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.

Yishai Ofran (Y)

Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.

Chezi Ganzel (C)

Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH